Key result
Inflammatory cardiomyopathy is linked to a ~30% transcardiac reduction in circulating mesenchymal stromal cells.
Observational (n=29)
No
Endogenous mesenchymal stromal cells continuously migrate to the heart in patients with inflammatory cardiomyopathy, a process strongly predicted by cardiac SDF-1α expression.
Answers are grounded in this paper and cite their sources.
Does not support practice changes; hypothesis-generating for MSC homing as therapeutic target in inflammatory cardiomyopathy.
Introduction. Mesenchymal stromal cells (MSC) have immunomodulatory features. The aim of this study was to investigate the migration and homing potential of endogenous circulating MSC in virus negative inflammatory cardiomyopathy (CMi). Methods. In 29 patients with (n = 23) or without (n = 6) CMi undergoing endomyocardial biopsies (EMB), transcardiac gradients (TCGs) of circulating MSC were measured by flow cytometry from blood simultaneously sampled from aorta and coronary sinus. The presence of MSC in EMB, cardiac inflammation, and SDF-1α mRNA expression were detected via immunohistochemistry and real-time PCR. Results. MSC defined as CD45(-)CD34(-)CD11b(-)CD73(+)CD90(+) cells accounted for 0.010 [0.0025-0.048]%/peripheral mononuclear cell (PMNC) and as CD45(-)CD34(-)CD11b(-)CD73(+)CD105(+) cells for 0.019 [0.0026-0.067]%/PMNC, both with similar counts in patients with or without cardiac inflammation. There was a 29.9% (P < 0.01) transcardiac reduction of circulating MSC in patients with CMi, correlating with the extent of cardiac inflammation (P < 0.05, multivariate analysis). A strong correlation was found between the TCG of circulating MSC and numbers of MSC (CD45(-)CD34(-)CD90(+)CD105(+)) in EMB (r = -0.73, P < 0.005). SDF-1α was the strongest predictor for increased MSC in EMB (P < 0.005, multivariate analysis). Conclusions. Endogenous MSC continuously migrate to the heart in patients with CMi triggered by cardiac inflammation.
No takes yet. Share an insight, caveat, or question.
Schmidt‐Lucke et al. (2015) conducted an observational in Inflammatory cardiomyopathy (n=29). Cardiac inflammation vs. No cardiac inflammation was evaluated on Transcardiac reduction of circulating mesenchymal stromal cells (p=<0.01). Patients with inflammatory cardiomyopathy demonstrated a significant 29.9% transcardiac reduction of circulating mesenchymal stromal cells compared to those without inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: